Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy

Journal of Internal Medicine

Volumn 278, Issue 1, 2015, Pages 50-58

  Hernandez Romero D ^a,b   Orenes Pinero E ^a,b   Garcia Honrubia A ^c   Climent, V ^d   Romero Aniorte, A I ^a,b   Martinez C M ^b,e   Garcia Bautista M ^f   Martinez M ^d   Feliu, E ^d   Gonzalez J ^a,b   Canovas S ^a   Montero Argudo, J A ^g   Valdes M ^a,b   Marin F ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca IMIB Arrixaca   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Departament of Molecular Biology   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Angiotensin converting enzyme; Fibrosis; Hypertrophic cardiomyopathy; Late gadolinium enhancement; Resistin

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; RESISTIN; GADOLINIUM; PEPTIDYL-DIPEPTIDASE A; RADIOISOTOPES; RETN PROTEIN, HUMAN;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MUSCLE RESECTION; PRIORITY JOURNAL; PROMOTER REGION; AGED; BLOOD; CARDIOMYOPATHY, HYPERTROPHIC; DIAGNOSTIC USE; FIBROSIS; GENETICS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MYOCARDIUM; PATHOLOGY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; FIBROSIS; GADOLINIUM; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RADIOISOTOPES; RESISTIN; SEVERITY OF ILLNESS INDEX;

EID: 84930931918     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12334     Document Type: Article

References (31)

1. Orenes-Piñero E, Hernández-Romero D, Jover E, de la Morena G, Valdés M, Marín F. An insight of novel pharmacological therapies in hypertrophic cardiomyopathy. Med Chem 2011; 7: 275-85.
2. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-91.
3. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-b1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118: 10-24.
4. Roldán V, Marín F, Gimeno JR et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J 2008; 156: 85-91.
5. Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48: 1977-85.
6. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-7.
7. Kaufman BD, Auerbach S, Reddy S et al. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Hum Genet 2007; 122: 515-23.
8. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation 2006; 113: 858-62.
9. Ortlepp JR, Vosberg HP, Reith S et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 2002; 87: 270-5.
10. Perkins MJ, Van Driest SL, Ellsworth EG et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005; 26: 2457-62.
11. Orenes-Piñero E, Hernández-Romero D, Jover E, Valdés M, Lip GY, Marín F. Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst 2011; 12: 521-30.
12. Danser AHJ, Schalekamp ADH. Is there an internal cardiac renin-angiotensin system? Heart 1996; 76: 28-32.
13. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86: 1913-20.
14. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
15. Tang NP, Wang LS, Yang L et al. A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin Endocrinol 2008; 68: 82-7.
16. Kim M, Oh JK, Sakata S et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45: 270-80.
17. Orenes-Piñero E, Hernández-Romero D, Romero-Aniorte AI et al. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. QJM 2014; 107: 613-21.
18. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997; 77: 130-2.
19. Dumont C, Monserrat L, Soler R et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 2007; 60: 15-23.
20. Bogaert J, Taylor AM, van Kerkhove F, Dymarkowski S. Use of inversion recovery contrast-enhanced MRI for cardiac imaging: spectrum of applications. Am J Roentgenol 2004; 182: 609-15.
21. Cerqueira MD, Weissman NJ, Dilsizian V et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 5439-42.
22. Hussain S, Asghar M, Javed Q. Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients. Transl Res 2010; 155: 142-7.
23. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87: 2520-4.
24. Cho YM, Youn BS, Chung SS et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentration in humans. Diabetologia 2004; 47: 559-65.
25. Azuma K, Oguchi S, Matsubara Y et al. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 2004; 36: 564-70.
26. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1085-6.
27. Tesson F, Dufour C, Moolman JC et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997; 29: 831-8.
28. Dellgren G, Eriksson MJ, Blange I, Brodin LA, Rådegran K, Sylvén C. Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis. Am J Cardiol 1999; 15: 909-13.
29. Yamada Y, Ichihara S, Fujimura T, Yokota M. Lack of association of polymorphisms of the angiotensin converting enzyme and angiotensinogen genes with nonfamilial hypertrophic or dilated cardiomyopathy. Am J Hypertens 1997; 10: 921-8.
30. Osterop AP, Kofflard MJ, Sandkuijl LA et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998; 32: 825-30.
31. Lindpaintner K, Lee M, Larson MG et al. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med 1996; 334: 1023-8.